Bragar Eagel & Squire Investigates uniQure (QURE) After 57% Stock Drop
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
Should l Buy QURE?
Source: Globenewswire
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating whether uniQure N.V. violated federal securities laws, particularly regarding the adequacy of data for the BLA submission of AMT-130, potentially exposing shareholders to losses.
- Severe Stock Volatility: A statement from uniQure on November 3, 2025, triggered a more than 57% drop in stock price during morning trading, reflecting market concerns over the future approval prospects of its drug.
- Investor Rights Protection: The law firm encourages all shareholders who invested in uniQure and suffered losses to contact them for legal advice and potential claims, emphasizing the importance of protecting investor rights.
- Uncertain Company Outlook: uniQure indicated that the FDA's declining recognition of AMT-130 data has led to uncertainty regarding the timing of the BLA submission, which could impact the company's long-term strategic development and market confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.940
Low
33.00
Averages
49.88
High
70.00
Current: 15.940
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Notification: Kahn Swick & Foti reminds investors who purchased uniQure shares between September 24 and October 31, 2025, to file lead plaintiff applications by April 13, 2026, to participate in the class action lawsuit against the company.
- Disclosure Violations: uniQure is accused of failing to disclose material information during the class period, misleading investors regarding the accelerated approval prospects of its drug candidate AMT-130, thus violating federal securities laws.
- Stock Price Plunge: Following the November 3, 2025 disclosure that the FDA no longer deemed the data for AMT-130 adequate, uniQure's stock price plummeted by 49%, from $67.69 to $34.29, resulting in significant investor losses.
- Legal Implications: This lawsuit could have profound financial implications for uniQure, as the economic losses faced by investors may compel the company to enhance transparency in its disclosures to mitigate similar legal risks in the future.
See More
uniQure Faces Unprecedented Federal Rebuke Amid Investigation
- Federal Officials Condemnation: On March 5, 2026, The Wall Street Journal reported that FDA officials accused uniQure of flawed clinical data regarding its Huntington's disease gene therapy, leading to unprecedented public criticism that severely undermined investor confidence in the company.
- Stock Price Collapse: Since November 3, 2025, uniQure's stock has plummeted nearly 84%, and following the WSJ report, shares fell over 49% due to the FDA's allegations, reflecting extreme market pessimism about the company's future prospects.
- Securities Class Action: A securities class action lawsuit has been filed against uniQure, covering investors who purchased shares between September 24 and October 31, 2025, alleging significant misrepresentations in key study designs and FDA interactions that may have led to substantial investor losses.
- Regulatory Investigation Intensification: Hagens Berman is conducting a thorough investigation into uniQure, focusing on whether the company's communications with the FDA contained misleading statements, which, if confirmed, could have profound implications for uniQure's legal and financial standing.
See More
uniQure Investors Encouraged to Seek Legal Options Amid Class Action
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential claims against uniQure N.V., particularly for investors who purchased securities between September 24, 2025, and October 31, 2025, aiming to provide legal support for affected investors.
- Class Action Notification: The firm reminds investors of the April 13, 2026, deadline to apply for lead plaintiff status in the federal securities class action filed against uniQure, necessitating timely action to protect their rights.
- Direct Contact Recommendation: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options and potential claims.
- Potential Impact Assessment: This legal action may negatively affect uniQure's stock price and market confidence, prompting investors to closely monitor the case's progress to adjust their investment strategies accordingly.
See More
Notice of Class Action Lawsuit Against uniQure
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval regarding the design of its pivotal study for its leading drug candidate for Huntington's Disease, resulting in investor losses when the true information was revealed.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record and extensive experience, urging investors to choose qualified legal counsel wisely.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, with no upfront fees required to join the class action, ensuring that investors' rights are protected.
See More
Kyndryl and uniQure Shareholder Lawsuit Reminder
- Kyndryl Lawsuit Overview: A shareholder class action lawsuit against Kyndryl Holdings, Inc. alleges that the company made materially false and misleading statements regarding its financial statements issued between August 7, 2024, and February 9, 2026, encouraging affected investors to contact legal counsel to discuss their rights if they suffered significant losses during this period.
- uniQure Lawsuit Details: The class action lawsuit against uniQure N.V. claims that the company failed to disclose material facts regarding the design of its pivotal study between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for investors to apply to be appointed lead plaintiff to protect their interests.
- Law Firm Background: Holzer & Holzer, LLC, recognized as an ISS top-rated securities litigation law firm for 2021, 2022, 2023, and 2025, has been dedicated to vigorously representing shareholders and investors since its founding in 2000, successfully recovering hundreds of millions of dollars for victims of corporate misconduct.
- Contact Information: Investors seeking more information or legal assistance can reach Corey D. Holzer, Esq. at (888) 508-6832 or via email at cholzer@holzerlaw.com, or visit the firm's website for additional resources.
See More
Hagens Berman Investigates Alleged Misstatements by uniQure
- Deadline Approaching: Hagens Berman reminds investors that the Lead Plaintiff Deadline for litigation against uniQure N.V. is April 13, 2026, urging affected investors to act quickly to protect their rights, highlighting the urgency and potential impact of the case.
- Allegations of Misstatements: The lawsuit alleges that uniQure made inaccurate and misleading statements regarding the regulatory path for its lead gene therapy candidate, AMT-130, particularly concerning the FDA's acceptance of a pivotal study design lacking a traditional placebo control, which could undermine investor confidence.
- Stock Price Plunge: Following the disclosure on November 3, 2025, that the FDA no longer agreed that AMT-130's data could support a BLA submission, uniQure's stock price fell by over 49%, reflecting extreme market pessimism regarding the company's prospects.
- Core Investigation Focus: Hagens Berman is investigating potential discrepancies between what uniQure communicated to investors about its interactions with the FDA and the details revealed in recent meeting minutes, which may further exacerbate concerns about the company's governance and transparency.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Notification: Kahn Swick & Foti reminds investors who purchased uniQure shares between September 24 and October 31, 2025, to file lead plaintiff applications by April 13, 2026, to participate in the class action lawsuit against the company.
- Disclosure Violations: uniQure is accused of failing to disclose material information during the class period, misleading investors regarding the accelerated approval prospects of its drug candidate AMT-130, thus violating federal securities laws.
- Stock Price Plunge: Following the November 3, 2025 disclosure that the FDA no longer deemed the data for AMT-130 adequate, uniQure's stock price plummeted by 49%, from $67.69 to $34.29, resulting in significant investor losses.
- Legal Implications: This lawsuit could have profound financial implications for uniQure, as the economic losses faced by investors may compel the company to enhance transparency in its disclosures to mitigate similar legal risks in the future.
See More
uniQure Faces Unprecedented Federal Rebuke Amid Investigation
- Federal Officials Condemnation: On March 5, 2026, The Wall Street Journal reported that FDA officials accused uniQure of flawed clinical data regarding its Huntington's disease gene therapy, leading to unprecedented public criticism that severely undermined investor confidence in the company.
- Stock Price Collapse: Since November 3, 2025, uniQure's stock has plummeted nearly 84%, and following the WSJ report, shares fell over 49% due to the FDA's allegations, reflecting extreme market pessimism about the company's future prospects.
- Securities Class Action: A securities class action lawsuit has been filed against uniQure, covering investors who purchased shares between September 24 and October 31, 2025, alleging significant misrepresentations in key study designs and FDA interactions that may have led to substantial investor losses.
- Regulatory Investigation Intensification: Hagens Berman is conducting a thorough investigation into uniQure, focusing on whether the company's communications with the FDA contained misleading statements, which, if confirmed, could have profound implications for uniQure's legal and financial standing.
See More
uniQure Investors Encouraged to Seek Legal Options Amid Class Action
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential claims against uniQure N.V., particularly for investors who purchased securities between September 24, 2025, and October 31, 2025, aiming to provide legal support for affected investors.
- Class Action Notification: The firm reminds investors of the April 13, 2026, deadline to apply for lead plaintiff status in the federal securities class action filed against uniQure, necessitating timely action to protect their rights.
- Direct Contact Recommendation: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options and potential claims.
- Potential Impact Assessment: This legal action may negatively affect uniQure's stock price and market confidence, prompting investors to closely monitor the case's progress to adjust their investment strategies accordingly.
See More
Notice of Class Action Lawsuit Against uniQure
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval regarding the design of its pivotal study for its leading drug candidate for Huntington's Disease, resulting in investor losses when the true information was revealed.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record and extensive experience, urging investors to choose qualified legal counsel wisely.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, with no upfront fees required to join the class action, ensuring that investors' rights are protected.
See More
Kyndryl and uniQure Shareholder Lawsuit Reminder
- Kyndryl Lawsuit Overview: A shareholder class action lawsuit against Kyndryl Holdings, Inc. alleges that the company made materially false and misleading statements regarding its financial statements issued between August 7, 2024, and February 9, 2026, encouraging affected investors to contact legal counsel to discuss their rights if they suffered significant losses during this period.
- uniQure Lawsuit Details: The class action lawsuit against uniQure N.V. claims that the company failed to disclose material facts regarding the design of its pivotal study between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for investors to apply to be appointed lead plaintiff to protect their interests.
- Law Firm Background: Holzer & Holzer, LLC, recognized as an ISS top-rated securities litigation law firm for 2021, 2022, 2023, and 2025, has been dedicated to vigorously representing shareholders and investors since its founding in 2000, successfully recovering hundreds of millions of dollars for victims of corporate misconduct.
- Contact Information: Investors seeking more information or legal assistance can reach Corey D. Holzer, Esq. at (888) 508-6832 or via email at cholzer@holzerlaw.com, or visit the firm's website for additional resources.
See More
Hagens Berman Investigates Alleged Misstatements by uniQure
- Deadline Approaching: Hagens Berman reminds investors that the Lead Plaintiff Deadline for litigation against uniQure N.V. is April 13, 2026, urging affected investors to act quickly to protect their rights, highlighting the urgency and potential impact of the case.
- Allegations of Misstatements: The lawsuit alleges that uniQure made inaccurate and misleading statements regarding the regulatory path for its lead gene therapy candidate, AMT-130, particularly concerning the FDA's acceptance of a pivotal study design lacking a traditional placebo control, which could undermine investor confidence.
- Stock Price Plunge: Following the disclosure on November 3, 2025, that the FDA no longer agreed that AMT-130's data could support a BLA submission, uniQure's stock price fell by over 49%, reflecting extreme market pessimism regarding the company's prospects.
- Core Investigation Focus: Hagens Berman is investigating potential discrepancies between what uniQure communicated to investors about its interactions with the FDA and the details revealed in recent meeting minutes, which may further exacerbate concerns about the company's governance and transparency.
See More
